Leqvio vs Amlodipine: What to Do When One Fails

Why Comparing These Two Drugs Directly Is the Wrong Frame

Inclisiran and amlodipine are not competitors in the clinical sense. They treat separate downstream risk factors for cardiovascular disease, LDL-driven atherosclerosis versus elevated blood pressure, and patients with established atherosclerotic cardiovascular disease (ASCVD) often need both running simultaneously.

The question "what to do when one fails" matters because patients and prescribers sometimes conflate general cardiovascular benefit with interchangeability. They are not interchangeable. Stopping inclisiran because blood pressure is still high, or stopping amlodipine because LDL-C is still elevated, leaves one entire risk pathway completely unmanaged.

The Two Risk Pathways These Drugs Target

Atherosclerotic plaque formation is driven partly by LDL-C accumulation in arterial walls. Inclisiran interrupts PCSK9 synthesis in hepatocytes, which prevents LDL receptors from being degraded, so the liver clears more circulating LDL-C. This mechanism operates entirely at the lipid level and has no meaningful blood pressure effect.

Elevated systolic blood pressure accelerates endothelial damage and increases cardiac afterload. Amlodipine blocks voltage-gated L-type calcium channels in vascular smooth muscle, causing vasodilation. This reduces peripheral vascular resistance and blood pressure. It has no meaningful effect on LDL-C.

What "Failure" Actually Means for Each Drug

For inclisiran, failure means LDL-C remains above the patient's individualized goal despite at least two confirmed injections at the correct 6-month interval. The 2019 ESC/EAS guideline recommends an LDL-C goal of <1.4 mmol/L (55 mg/dL) for very high-risk patients, and <1.8 mmol/L (70 mg/dL) for high-risk patients [1].

For amlodipine, failure is either pharmacological (BP remains above goal after 8 to 12 weeks at 10 mg daily) or tolerability-driven (peripheral edema, flushing, or reflex tachycardia that does not resolve within 4 weeks of dose reduction).

Inclisiran (Leqvio): Mechanism, Evidence, and Failure Scenarios

How Inclisiran Works at the Molecular Level

Inclisiran is a synthetic double-stranded siRNA conjugated to triantennary N-acetylgalactosamine (GalNAc), which directs it to hepatocytes via asialoglycoprotein receptors. Once inside the cell, the RISC complex uses the antisense strand to silence PCSK9 mRNA, reducing PCSK9 protein production. Fewer PCSK9 proteins means LDL receptors are recycled rather than degraded, increasing hepatic LDL uptake.

The half-life of the effect is long because the siRNA integrates into the RISC complex rather than requiring constant drug exposure. This is why dosing every 6 months is sufficient after the initial loading period.

What the ORION Trials Showed

ORION-10 and ORION-11 (NEJM 2020, pooled N=3,457) are the key phase 3 trials. In ORION-10, inclisiran 300 mg produced a 52.3% placebo-adjusted reduction in LDL-C at day 510. In ORION-11, the reduction was 49.9% [2]. Both trials enrolled patients with established ASCVD or ASCVD risk equivalents who were already on maximally tolerated statin therapy.

Adverse event rates were similar to placebo except for injection-site reactions, which occurred in roughly 2.6% of inclisiran patients versus 0.9% of placebo patients. There were no meaningful increases in liver enzymes, myalgias, or neurocognitive events.

Scenarios Where Inclisiran Appears to Fail

Residual LDL-C elevation despite correct dosing. Some patients with familial hypercholesterolemia (FH) carry two defective LDLR alleles (homozygous FH). In homozygous FH, LDL receptors are absent or nearly absent, so increasing their recycling via PCSK9 inhibition produces minimal LDL-C lowering. These patients may need lomitapide or evinacumab.

Missed or delayed injections. If the day-90 dose is delayed by more than 3 months, the drug must be restarted on the original schedule. Clinically, LDL-C may rebound toward baseline during the gap, which mimics "failure" but is actually a dosing error.

Statin withdrawal during inclisiran therapy. Inclisiran's approved indication includes concurrent statin use in most patients. If a statin is stopped, LDL-C may rise enough to remain above goal even though inclisiran is working correctly. The problem is statin discontinuation, not inclisiran failure.

True pharmacological insufficiency. A small subset of heterozygous FH patients with very high baseline LDL-C (above 200 mg/dL) may not reach goal on inclisiran plus maximally tolerated statin. In this group, adding ezetimibe 10 mg daily first is the standard next step before considering additional agents.

Amlodipine: Mechanism, Evidence, and Failure Scenarios

How Amlodipine Lowers Blood Pressure

Amlodipine blocks the slow inward calcium current in vascular smooth muscle cells, reducing intracellular calcium and triggering relaxation. The result is systemic arteriolar vasodilation and reduced afterload. Because amlodipine has a very long plasma half-life (30 to 50 hours), once-daily dosing produces stable 24-hour blood pressure control without large troughs.

What ASCOT-BPLA Showed

ASCOT-BPLA (Lancet 2005, N=19,257) compared amlodipine-based therapy (amlodipine plus perindopril as needed) versus atenolol-based therapy (atenolol plus bendroflumethiazide as needed). The amlodipine arm achieved a 2.7 mmHg lower mean systolic blood pressure and a 23% relative reduction in the primary endpoint of nonfatal myocardial infarction and fatal coronary heart disease [3]. The trial was stopped early at a median follow-up of 5.5 years due to the clear superiority of the amlodipine arm.

The ACC/AHA 2017 hypertension guideline (which defines stage 1 hypertension as systolic BP 130 to 139 mmHg) names thiazide diuretics, ACE inhibitors/ARBs, and CCBs including amlodipine as first-line agents for most patients [4].

Scenarios Where Amlodipine Appears to Fail

Insufficient dose titration. Amlodipine is available from 2.5 mg to 10 mg daily. Many patients are started at 5 mg and never titrated. If BP remains above goal at 5 mg with good tolerability, escalating to 10 mg is the first step.

Resistant hypertension. The ACC/AHA defines resistant hypertension as BP above goal despite three antihypertensives at optimized doses, one of which is a diuretic. Roughly 10 to 13% of hypertensive patients meet this definition [5]. In resistant hypertension, amlodipine is typically continued while a mineralocorticoid receptor antagonist such as spironolactone 25 to 50 mg daily is added. The PATHWAY-2 trial (BMJ 2015, N=335) showed spironolactone was the most effective fourth-line agent.

Intolerable peripheral edema. Ankle edema occurs in approximately 10.8% of patients taking amlodipine 10 mg [6]. Switching to a dihydropyridine with a different edema profile, such as lercanidipine (where available), or switching class to an ARB or ACE inhibitor, is appropriate when edema does not resolve within 4 weeks of dose reduction to 5 mg.

White-coat effect masking true response. Some patients appear non-responsive on office readings but show adequate control on 24-hour ambulatory blood pressure monitoring (ABPM). Before labeling amlodipine a failure, ABPM should confirm true uncontrolled hypertension.

What to Do When Inclisiran Fails: A Step-by-Step Clinical Pathway

The following pathway applies to patients with established ASCVD or FH who remain above LDL-C goal after at least two inclisiran injections confirmed to have been administered correctly.

Step 1: Confirm the Failure Is Real

Check injection records. Confirm both the day-1 and day-90 doses were given, then that subsequent 6-month doses were on schedule. Order a fasting lipid panel no sooner than 4 weeks after the most recent injection. A lipid panel drawn within days of injection may not yet reflect the full pharmacodynamic response.

Step 2: Optimize the Statin

If the patient is on a moderate-intensity statin, escalate to high-intensity statin therapy (rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg). The 2022 ACC Expert Consensus Decision Pathway recommends confirming maximally tolerated statin before adding or switching non-statin agents [7].

Step 3: Add Ezetimibe

Ezetimibe 10 mg daily reduces LDL-C by an additional 18 to 20% on top of statin therapy. The IMPROVE-IT trial (NEJM 2015, N=18,144) showed that adding ezetimibe to simvastatin after acute coronary syndrome reduced the primary composite cardiovascular endpoint by 6.4% over 7 years compared to simvastatin alone (32.7% vs 34.7%, P<0.001) [8].

Step 4: Evaluate for Homozygous FH

If the patient has a confirmed homozygous FH genotype or phenotypic LDL-C persistently above 500 mg/dL despite full combination therapy, inclisiran is unlikely to provide adequate additional reduction. Refer to a lipid specialist for consideration of lomitapide (an MTP inhibitor) or evinacumab (an anti-ANGPTL3 monoclonal antibody).

Step 5: Consider PCSK9 Monoclonal Antibodies as an Alternative

Evolocumab (Repatha) and alirocumab (Praluent) are monoclonal antibodies that block the PCSK9 protein directly, compared to inclisiran's upstream mRNA silencing approach. The FOURIER trial (NEJM 2017, N=27,564) showed evolocumab reduced LDL-C by 59% and reduced the primary MACE composite by 15% versus placebo over a median of 2.2 years [9]. If inclisiran genuinely produces less-than-expected LDL-C lowering in a specific patient, switching to a PCSK9 monoclonal antibody is a reasonable trial to determine whether the mechanism class or the patient's individual PCSK9 biology is the limiting factor.

What to Do When Amlodipine Fails: A Step-by-Step Clinical Pathway

Step 1: Maximize the Dose and Check Adherence

Titrate to amlodipine 10 mg daily if tolerated. Pill count and pharmacy refill data can help identify adherence gaps. BP readings should be obtained 12 to 24 hours after the last dose to capture trough efficacy.

Step 2: Add a Renin-Angiotensin System (RAS) Blocker

ASCOT-BPLA demonstrated that the combination of amlodipine plus an ACE inhibitor (perindopril) outperformed the beta-blocker plus thiazide combination. Adding an ACE inhibitor such as ramipril 5 to 10 mg or an ARB such as olmesartan 20 to 40 mg is the first recommended intensification step in most ACC/AHA and ESC hypertension guidelines.

Step 3: Add a Thiazide or Thiazide-Like Diuretic

Chlorthalidone 12.5 to 25 mg daily or indapamide 1.25 to 2.5 mg daily provides additive BP lowering through a distinct mechanism (reducing plasma volume). The SPRINT trial (NEJM 2015, N=9,361) showed that targeting a systolic BP below 120 mmHg with intensive multidrug therapy reduced cardiovascular events by 25% and all-cause mortality by 27% versus the 140 mmHg target [10].

Step 4: Manage Intolerable Edema

For patients who cannot tolerate amlodipine-associated edema at doses needed for BP control, switching to a non-dihydropyridine CCB (diltiazem or verapamil) is one option, though heart-rate effects must be monitored. Alternatively, switching class to an ARB or ACE inhibitor as monotherapy may be appropriate if the patient also has diabetes or proteinuria.

Step 5: Address Resistant Hypertension

Meeting the resistant hypertension definition triggers a specific evaluation: rule out secondary causes (primary hyperaldosteronism, renal artery stenosis, obstructive sleep apnea, pheochromocytoma). Add spironolactone 25 mg daily as fourth-line therapy per PATHWAY-2 evidence. Referral to a hypertension specialist or nephrologist is appropriate if three-drug maximum-dose therapy fails.

Can You Be on Both Inclisiran and Amlodipine at the Same Time?

Yes. Most patients with established ASCVD have both elevated LDL-C and hypertension. The ACC/AHA 2019 guideline on cardiovascular risk reduction explicitly addresses lipid and blood pressure management as parallel, independent treatment pathways [11].

There are no known pharmacokinetic interactions between inclisiran and amlodipine. Inclisiran is cleared via nuclease metabolism and renal excretion. Amlodipine is metabolized by CYP3A4. The two drugs do not share metabolic pathways.

A common clinical scenario is a post-MI patient on high-intensity statin plus inclisiran for LDL-C control, and amlodipine plus an ACE inhibitor for blood pressure and angina management. These regimens complement each other.

Special Populations and Dosing Considerations

Chronic Kidney Disease (CKD)

Inclisiran does not require dose adjustment in CKD stages 1 through 4. The drug was studied in patients with eGFR as low as 15 mL/min/1.73m2. Amlodipine also requires no renal dose adjustment, though these patients often have additional antihypertensive needs given the high prevalence of resistant hypertension in CKD.

Older Adults

Amlodipine is generally well tolerated in adults over age 65. The primary concern is orthostatic hypotension at higher doses. Starting at 2.5 mg and titrating slowly over 4-week intervals reduces this risk. For inclisiran, no dose modification is required for age alone.

Patients with Diabetes

Amlodipine is metabolically neutral, unlike beta-blockers and thiazide diuretics which may worsen glycemia. The ASCOT-LLA substudy showed that patients in the amlodipine arm had lower rates of new-onset diabetes than patients in the atenolol arm (relative risk reduction 30%) [3]. Inclisiran has no effect on glucose metabolism.

Side-by-Side Clinical Reference

| Feature | Inclisiran (Leqvio) | Amlodipine | |---|---|---| | Drug class | siRNA / PCSK9 inhibitor | Dihydropyridine CCB | | Primary use | Lower LDL-C | Lower blood pressure | | Dose | 300 mg subcutaneous, every 6 months | 2.5 to 10 mg oral, once daily | | LDL-C effect | ~50% reduction | Negligible | | BP effect | Negligible | 9 to 14 mmHg systolic reduction | | Common side effects | Injection-site reactions (~2.6%) | Peripheral edema (~10.8% at 10 mg) | | Renal dose adjustment | Not required | Not required | | CYP interactions | None known | CYP3A4 substrate | | Cost/access | Specialty pharmacy, prior auth often required | Generic, widely available |

Monitoring Schedule After Adjusting Either Drug

When inclisiran is added or its companion statin is adjusted, a fasting lipid panel should be checked 4 to 12 weeks after the change. The ACC/AHA 2022 Expert Consensus recommends confirming LDL-C response at 4 to 12 weeks and then annually once at goal [7].

When amlodipine is titrated, a clinic blood pressure check or home BP log review at 2 to 4 weeks confirms the dose response. Once stable at goal, blood pressure review every 3 to 6 months is standard per ACC/AHA guidance [4].

Electrolytes (potassium, sodium, creatinine) should be checked 2 to 4 weeks after adding any RAS blocker or thiazide to an amlodipine regimen.